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Post-infectious  immunity  to respiratory  syncytial  virus  (RSV)  infection  results  in  limited  protection  as
evidenced  by the high  rate  of infant hospitalization  in  the  face  of  high  titer,  maternally  derived  RSV-
speciﬁc  antibodies.  By contrast,  RSV  fusion  (F)  glycoprotein  antigenic  site  II humanized  monoclonal
antibodies,  palivizumab  and  motavizumab,  have  been  shown  to reduce  RSV-related  hospitalization  in
infants.  Immunogenicity  and  efﬁcacy  studies  were  conducted  in cotton  rats  comparing  a recombinant
RSV  F  nanoparticle  vaccine  with  palivizumab  and  controlled  with  live  RSV  virus  intranasal  immunization
and,  formalin  inactivated  RSV  vaccine.  Active  immunization  with  RSV  F  nanoparticle  vaccine  containing
an  alum  adjuvant  induced  serum  levels  of  palivizumab  competing  antibody  (PCA)  greater  than  passive
administration  of 15 mg/kg  palivizumab  (human  prophylactic  dose)  in  cotton  rats  and  neutralized  RSV-A
and  RSV-B  viruses.  Immunization  prevented  detectable  RSV replication  in  the  lungs  and,  unlike passive
administration  of  palivizumab,  in the  nasal  passage  of  challenged  cotton  rats.  Histology  of  lung  tissues
following  RSV  challenge  showed  no enhanced  disease  in the  vaccinated  groups  in  contrast  to  formalin
inactivated  ‘Lot  100’  vaccine.  Passive  intramuscular  administration  of RSV F vaccine-induced  immuneanoparticles
otton rat
sera  one  day  prior  to  challenge  of  cotton  rats  reduced  viral  titers  by  2 or more  log10 virus  per gram  of
lung  and  nasal  tissue  and at doses  less  than  palivizumab.  A recombinant  RSV F  nanoparticle  vaccine  pro-
tected  lower  and  upper  respiratory  tract against  both  RSV  A and  B  strain  infection  and  induced  polyclonal
palivizumab  competing  antibodies  similar  to  but  potentially  more  broadly  protective  against  RSV  than
palivizumab.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Respiratory syncytial virus (RSV) is the leading cause of severe
ower respiratory tract disease in infants and young children world-
ide [1] and is an important pathogen in elderly and high risk
dults [2]. The World Health Organization (WHO) has estimated
hat the global annual burden of infections and mortality due to
uman RSV are 64 million and 160,000, respectively [3]. In indus-
rialized countries, nearly all children have been infected with RSV
y 2 years of age [4]. Most infected children present with mild
pper respiratory tract symptoms, but a subset develops severe
ower respiratory tract disease characterized by tachypnea, hyper-
nﬂation, crackles, and expiratory wheezing (i.e., bronchiolitis and
∗ Corresponding author. Tel.: +1 240 268 2138; fax: +1 240 268 2100.
E-mail address: rraghunandan@novavax.com (R. Raghunandan).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.030
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
pneumonia). The most severe disease occurs within the ﬁrst
months of life in largely full term, healthy infants. Data from the
United States (US) and Australia suggest that 1.7–2.6% of infants
are hospitalized for RSV infection before one year of age [5–7]. In
the US, approximately 75,000–100,000 infants less than 1 year of
age [8,9] and 132,000–172,000 children less than 5 years of age [10]
are hospitalized due to RSV disease annually. RSV is an important
pathogen of children in daycare, where it accounts for a substan-
tial portion of single-pathogen acute respiratory tract infections,
as well as co-infections with rhinoviruses, coronaviruses, or aden-
oviruses [11]. The clinical manifestations and morbidity of RSV are
similar among infants and young children worldwide but mortality
is much higher in the lesser developed countries due to availability
of medical care [12].
Despite  decades of research there is no licensed RSV vaccine
[13]. However, two monoclonal antibodies, palivizumab (Synagis®)
and motavizumab, both of which bind to the fusion protein of the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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irus, have been shown to prevent severe disease in premature
nd term infants by passive immunoprophylaxis [14–16]. The efﬁ-
acy is associated with inhibition of viral infection via binding to a
5 amino acid sequence known as “antigenic site II” on the RSV F
rotein which provides a rationale for an F based RSV vaccine con-
aining this site [17]. Recent clinical trials have indicated that years
f natural infection and thus exposure to live virus, induces little or
o F speciﬁc site II antibodies [18].
There are two major RSV strains that co-circulate in humans,
SV-A and -B. In both strains, two surface glycoproteins, F and G,
ngage the host cell to establish and propagate infection respec-
ively [19]. The human RSV viral attachment G glycoprotein is
enetically diverse [20], compared to the more highly conserved
-fusion glycoprotein [21]. Natural infection is frequent in all
ge groups and results in signiﬁcant immune responses to the F
nd G glycoproteins, but only the highest levels of neutralizing
ntibodies appear to confer solid protection against reinfection
22–24].
The RSV F nanoparticle vaccine is a recombinant near-full length
 glycoprotein produced in Spodoptera frugiperda (Sf9) insect cells
ith a recombinant baculovirus [25]. Puriﬁed recombinant RSV F
ligomers are hatpin-shaped rods, consistent with a post-fusion-
ike conformation of RSV F [26–29]. Cotton rats immunized with
his vaccine have demonstrated protection against RSV replica-
ion [25]. In the current study the production of vaccine-induced
alivizumab competing antibodies (PCA) that bind to site II were
tudied in cotton rats to assess their relative potency, both in active
nd passive immunization. The studies were also controlled with
SV infection, which has been shown to induce very limited PCA
n humans [18]. Finally, Lot 100 formalin inactivated RSV vaccine,
sed in the 1960’s and associated with disease enhancement in
hildren, allowed comparison of relative safety and the induction
f functional immunity.
.  Materials and methods
.1.  Vaccine
Brieﬂy, the RSV F protein nanoparticle vaccine was  manufac-
ured by infecting Sf9 cells in exponential growth with baculovirus
ontaining the RSV F gene, as previously described [25]. After
nfection, cells are collected by centrifugation, washed with sterile
BS, and then lysed in the presence of NP9 to release mem-
rane bound RSV F protein. The supernatant containing the RSV
 protein is clariﬁed using depth ﬁltration and then puriﬁed
y ion exchange (trimethylaminoethyl, TMAE) chromatography.
he ﬂow-through fraction is afﬁnity puriﬁed using lentil lectin
ashed and eluted from the column with buffer containing
ethyl--d-mannopyranoside (MMP)  and polysorbate (PS) 80. The
luted fraction was further puriﬁed by cation exchange (sulfate)
hromatography. The product was sterile ﬁltered (0.22 m)  and
ormulated with buffer containing 25 mM sodium phosphate, pH
.2, 1% histidine, 0.01% PS80. The vaccine was adsorbed to alu-
inum phosphate (aluminum as phosphate salt in 0.15 M NaCl
ithout buffer) purchased from Brenntag Biosector, Frederikssund,
enmark.
.2. Animals
Inbred 6–8 weeks Sigmodon hispidus (cotton rats) were obtained
rom Sigmovir Biosystems, Inc. (Rockville, MD). All studies were
onducted in accordance with the NRC Guide for the Care and Use
f Laboratory Animals, the Animal Welfare Act and the CDC/NIH
iosafety in Microbiological and Medical Laboratories under appli-
able laws and guidelines and were approved by the Institutional
nimal Care and Use Committee (IACUC).e 32 (2014) 6485–6492
2.3.  FI-RSV virus, RSV virus
Lot  100 formalin-inactivated RSV vaccine (FI-RSV) manufac-
tured by Pﬁzer in mid-1960s [30], and RSV-A Long and RSV-B 18537
were provided by Sigmovir Inc. The RSV–A viruses were propagated
in HEp-2 cells. A pool of virus designated as hRSV-A Long Lot no.
021413 at approximately 2.0 × 107 plaque forming units (pfu)/ml
was stored at −80 ◦C. RSV-B 18537 (RSV-B) (ATCC, Manassas, VA)
was propagated in MA-104 cells. A pool of virus designated as hRSV-
B Lot no. 12/03, at approximately 2.7 × 106 pfu/ml 10% was stored
at −80 ◦C.
2.4. Immunization and RSV challenge in cotton rats
Cotton rats (n = 8) were immunized intramuscularly (IM) on
day 0 and 28 with FI-RSV, RSV-F nanoparticle vaccine with and
without adjuvant, RSV A 1 × 105 pfu intranasally and compared to
palivizumab 15 mg/kg given IM,  one day prior to challenge. Sera
were obtained on day 0, 28, 49 and on day 54 post-challenge. RSV
challenge was  performed on day 49 intranasally with 1 × 105 pfu in
100 l (50 l/nare) RSV-A Long strain and lung tissue collected on
day 54.
For  the dose-descalation active immunization study, cotton rats
received two vaccinations of 0.003, 0.03, 0.3, or 3.0 g RSV F vaccine
adjuvanted with aluminum phosphate on Day 0 and Day 21 and
compared to palivizumab 5.0, 2.5, 1.25 or 0.625 mg/kg IM on day
41. Sera were obtained on day 0, 21, 42 prior to challenge, on day
46 post-challenge and stored at −20 ◦C until tested.
A pool of immune sera from RSV F nanoparticle vaccine-
immunized cotton rats was prepared and assayed in the PCA ELISA
as described below. Cotton rats (n = 5/group) were then passively
immunized by IM with 0.6, 1.4 or 5.6 mg/kg of palivizumab-like
antibody activity and compared to palivizumab given at 5.0, 2.5,
1.25 or 0.625 mg/kg IM on day 41. RSV challenge was performed
on day 42 by intranasal administration of 100 l (50 l/nare) live
RSV-B 18537 (1 × 105 pfu). Cotton rats were bled on Day 0, 21 and
Day 42 following one and two immunizations and on Day 46 (4
days after challenge). Nasal wash, BAL, nose and lung tissues were
collected on Day 46.
2.5.  RSV F ELISA, palivizumab competitive antibody (PCA) ELISA
and  neutralization assay
RSV  F-speciﬁc antibodies in cotton rat sera were measured
in an enzyme linked immunosorbent assay (ELISA) as previously
described [25]. Competitive inhibition by cotton rat sera of the
binding of palivizumab monoclonal antibody (ASD Specialty Heath
Care Inc., Chicago IL) was measured by an ELISA method as pre-
viously described [25]. Serum RSV virus neutralization titers were
determined as described previously [25].
2.6. Lung viral load determination and pulmonary histopathology
Five days after intranasal RSV challenge, cotton rats were sac-
riﬁced and the lungs harvested. Lung tissues were homogenized
and clariﬁed by centrifugation at 12,000 × g for 10 min. Virus titer
in the supernatant was determined by plaque assay as described
previously [25]. Lung tissue slides were stained with hematoxylin,
eosin (H&E) and observed under a Nikon Eclipse microscope. Slides
were evaluated in a blinded fashion using a score of 0–4 (0 = none;
1 = minimal; 2 = mild; 3 = moderate; 4 = maximum inﬂammation) in
order of increasing severity for each of the following 5 parame-
ters: (a) peribronchiolitis; (b) perivasculitis; (c) bronchoiolitis; (d)
alveolitis and (e) interstitial pneumonitis as described by Prince
accine 32 (2014) 6485–6492 6487
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Fig. 1. Immune responses to the RSV F nanoparticle vaccine. Cotton rats (n = 8) were
immunized on day 0 and 28 with FI-RSV, RSV-A2, or RSV-F nanoparticle vaccine
with  and without AdjuPhos. An additional group received palivizumab 15 mg/kg
intramuscularly  on day 48, one day prior to challenge. A placebo group served as a
negative control. Sera were obtained from all the groups on day 49, prior to chal-
lenge.  Panel A. RSV F IgG responses as determined by ELISA; expressed as log10 of the
GMT with 95% CI. Panel B. Palivizumab competing antibody (PCA) were reported as
the g/ml (log2) antibodies required for 50% inhibition of binding of palivizumab to
RSV F. Panel C. Neutralizing antibody titers against RSV-A2 providing 60% inhibition
of CPE (log2). GMT  for each group is shown with the 95% CI. *p values <0.01; NS: not
signiﬁcant compared with RSV-infection group by two-tailed Student t-test; LOD  isR. Raghunandan et al. / V
t al. [31]. Summary scores for animals in each group were used to
enerate an overall score/group expressed as the arithmetic
ean + SEM of the individual animals.
.7.  Statistical methods
Comparisons  between mean scores of each group and non-
mmune animal challenge scores were analyzed using Student’s
-test. The sum of the scores of ﬁve parameters per animal was used
or analysis of histopathology data. Pair wise t-test was analyzed in
XCEL while the GMT  and 95% CI were calculated using Graph Pad
rizm.
. Results
.1. RSV F vaccine induced immune responses compared to
alivizumab
Immune  responses to RSV F nanoparticle vaccine (30 g) admin-
stered IM in the presence or absence of adjuvant were compared
o animals that received passively transferred palivizumab at the
ecommended human dose of 15 mg/kg. As controls, animals were
nfected with 105 pfu of RSV-A Long and allowed to recover, or
accinated with FI-RSV (Lot 100 at 1:25 dilution), or treated with
lacebo. Three weeks after the second vaccine dose the immuniza-
ion with unadjuvanted RSV F nanoparticle vaccine had induced
iters of anti-RSV F serum IgG (Fig. 1A) that were signiﬁcantly
igher (p < 0.001, t-test) than cotton rats immunized with FI-RSV
ntigen or infected with RSV-A virus (p < 0.001, t-test). Adjuvant
nhanced RSV F vaccine antibody titers by about 10-fold after
he boost (Fig. 1A). Cotton rats that received palivizumab (IM
njection) exhibited lower anti-RSV F IgG serum titers compared
o the polyclonal responses obtained following immunization
ith adjuvanted RSV F (GMT = 1926 vs 1469,084 E.U., respectively
ig. 1A).
Antigenic site II on the RSV F polypeptide is the target of
alivizumab [32]. A palivizumab competitive ELISA was  performed
o quantify the relative levels of PCA antibody induced by the
accine in animal sera. Immunization with 30 g adjuvanted RSV
 nanoparticles elicited signiﬁcantly higher serum levels of PCA
884 g/ml) than animals that received 15 mg/kg (human dose)
f palivizumab (86 g/ml). PCA was below the LOD of the assay
<20 g/ml) in cotton rats immunized with FI-RSV, and naïve
ontrol groups, and slightly above LOD in the RSV A intranasal
mmunization group (Fig. 1B).
Sera from all groups, with the exception of FI-RSV and placebo
ecipients, had virus neutralizing antibodies (Fig. 1C). Adjuvanted
SV F elicited higher neutralization titers (GMT = 697) than nat-
ral infection (GMT = 95) or palivizumab passively immunized
otton rats (GMT = 320) (Fig. 1C). The neutralizing titer differences
bserved between cotton rats that received adjuvanted RSV F and
irus infected cotton rats were statistically signiﬁcant (p < 0.01) fol-
owing the same trend observed from analysis of PCA and anti-RSV
 ELISA responses.
.2.  In vivo efﬁcacy of RSV F nanoparticle vaccine
The in vivo efﬁcacy of RSV F nanoparticle vaccine was evalu-
ted by measuring inhibition of viral replication in the lungs and
asal passages of immunized cotton rats challenged with RSV. Com-
lete inhibition of virus replication was observed in the lungs of
otton rats immunized with live RSV, RSV F nanoparticles admin-
stered with and without adjuvant, as well as palivizumab given
assively (Fig. 2A). FI-RSV reduced lung viral load (pfu/g tissue;the lower limit of detection.
GMT  = 2357) when compared to naïve challenged cotton rats (pfu/g
tissue; GMT  = 194,237) but failed to confer full protection. When
viral replication was evaluated in the nasal compartment, only the
RSV F vaccine with adjuvant and RSV infection groups were com-
pletely protected (Fig. 2B). Cotton rats that received unadjuvanted
RSV F and palivizumab had reduced viral load compared to the
naïve animal group but with readily measurable virus titers in nasal
tissue following challenge (Fig. 2B).
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Fig. 2. RSV-A Long viral tiers from post challenge lung and nasal tissue of cotton rats.
Cotton rats (n = 8) were immunized on day 0 and 28 with FI-RSV, RSV-A Long (IN-
infection), or RSV-F nanoparticle vaccine with and without AlP04. An additional
group  received palivizumab 15 mg/kg via intramuscular injection on day 48 one day
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5rior to challenge. All groups were challenged on day 49. Panel A. Virus, log10 pfu/g
ung tissue, GMT  shown as a bar. Panel B. Virus log10 pfu/g nasal tissue *p < 0.01 com-
ared to RSV infection and RSV F-alum groups; LOD is the lower limit of detection.
.3. Comparative histopathology of the RSV F nanoparticle
accine and FI-RSV vaccine
When  Lot 100 FI-RSV vaccine was used in a clinical trial in the
ate 1960s, vaccinated children developed enhanced respiratory
isease (ERD) upon reinfection [33]. Similarly, ERD can be repro-
uced in the cotton rat model with the same vaccine, known as
ot 100 FI-RSV vaccine [30,31]. In the current study, Lot 100 FI-
SV induced prominent alveolitis and perivasculitis in the lungs of
SV challenged animals, consistent with ERD. Conversely, signif-
cant lung histopathological changes of this magnitude were not
bserved in cotton rats immunized with the RSV F nanoparticle
accine administered with or without adjuvant and were similar
o the minimal changes seen in placebo and palivizumab animals
Fig. 3A–C).
.4.  Low doses of RSV F nanoparticle vaccine and protection in
otton  rats
The  RSV F vaccine was derived from the RSV A long sequence.
 dose ranging immunization with the RSV F vaccine was under-
aken to compare the protective efﬁcacy of the vaccine against a
on-homologous challenge (RSV B) with palivizumab, known to
e protective against both RSV A and B [34]. Cotton rats weree 32 (2014) 6485–6492
immunized  with 0.003, 0.03, 0.3 or 3.0 g doses of adjuvanted RSV
F vaccine on day 0 and 21. Palivizumab was  given at a dose of 0.62,
1.25, 2.5 or 5.0 mg/kg one day prior to challenge.
RSV  F nanoparticle vaccine and palivizumab induced serum
anti-RSV F IgG titers that were high and dose dependent
(GMT  = 12,998–310,439, GMTs = 4626–95,441, respectively;
Fig. 4A). Similarly the levels of PCA were robust for all groups
that received the adjuvanted RSV F vaccine. PCA titers in animals
passively transferred with palivizumab were signiﬁcantly lower
and only observed at the 5 and 2.5 mg/kg doses (30, 16 g/ml).
Cotton rats receiving 0.625 and 1.25 mg/kg palivizumab had PCA
titers below the level of detection (10 g/ml) (Fig. 4B). Neutralizing
antibodies to RSV-A and RSV-B were induced in a dose-dependent
manner (Fig. 4C). Even the lowest dose of 0.003 g RSV F vaccine
induced signiﬁcant levels of neutralizing antibody against both
RSV-A Long and RSV-B 18537. Neutralizing titers in the 5.0 mg/kg
palivizumab group were comparable to those induced in animals
actively immunized with the lowest dose of 0.003 g RSV F vaccine
(Fig. 4C and D).
The  in vivo protective efﬁcacy of the RSV F nanoparticle vaccine
was evaluated in direct comparison to palivizumab by measur-
ing inhibition of viral replication in the lungs and nasal passages
of cotton rats challenged with RSV-B 18537. Post-challenge lung
virus titers (GMT) were just above the LOD in animals given the
lowest dose of RSV F (0.003 g) and were below the LOD in recip-
ients of higher doses of RSV F vaccine (Fig. 5A). The RSV lung virus
titer was  4.5 log10 in the placebo group (Fig. 5A). Palivizumab also
reduced lung RSV titers to below the LOD, with more detectable
virus in the lowest doses consistent to what has been previously
observed [34]. Reduction of RSV titers in the nasal passages was
also observed in a dose dependent manner for both the RSV F
vaccine and palivizumab, with relatively lower virus levels in the
RSV F vaccine group in concert with the levels of neutralizing
titers induced (Fig. 5B). Thus, the RSV F vaccine was protective
against non-homologous virus challenge in the upper and lower
respiratory tract and appears to be a potent immunogen that pro-
vided protection via active immunization exceeding that seen with
palivizumab, despite the use of very low doses of vaccine.
3.5.  RSV F vaccine-induced antibody and palivizumab in passive
immunoprophylaxis
A  passive immunization-virus challenge study was done to com-
pare the relative potency of the vaccine, as measured by the PCA
assay, relative to palivizumab. Cotton rats received IM injections of
a pooled cotton rat anti-RSV F serum that delivered PCA doses of
5.6, 1.6 or 0.6 mg/kg or a similar range of palivizumab at 5.0, 1.3
or 0.6 mg/kg one day prior to RSV challenge. At 24 h after adminis-
tration of anti-RSV F antibodies, the levels of RSV F IgG antibodies
were high and dose dependent for all the groups with the exception
of the group that received normal cotton rat serum (Fig. 6C). The
titers were similar for the highest dose of palivizumab and immune
anti-sera administered (GMT = 24,166 and 26,636, respectively).
One day following passive immunization (day 0), PCA levels
were signiﬁcantly higher for groups that received RSV F anti-sera
(p < 0.01) than those given a similar dose of palivizumab, as mea-
sured by the PCA assay (Fig. 6A). In palivizumab treated animals,
PCA serum titers were at or below the LOD for the assay except
at the highest dose, whereas the PCA serum levels in cotton rats
passively immunized with anti-RSV F serum were 183 g/ml and
53 g/ml at the 5.6 and 1.4 mg/kg dose levels, respectively.
All groups were challenged 24 hours after passive immunization
(day 0) with 10 pfu RSV-A Long virus. Lung tissues were collected
on day 4 post challenge to determine viral titer by plaque assay
on homogenized tissue. The highest doses of anti-RSV F immune
sera (5.6 mg/kg) and palivizumab (5.0 mg/kg) conferred apparently
R. Raghunandan et al. / Vaccine 32 (2014) 6485–6492 6489
Fig. 3. Cotton rat lung histopathology. Cotton rats (n = 8) were immunized on day 0 and 28 with FI-RSV, RSV-A Long (IN-infection), or RSV-F nanoparticle vaccine with and
without AlPO4. An additional group received palivizumab 15 mg/kg via intramuscular injection on day 48 a day prior to challenge. All groups were challenged on day 49 with
RSV-A  Long virus. Lung tissue isolated 5 days after challenge were frozen, sectioned, and stained with hematoxylin and eosin from all the groups. Panel A. Histopathology
scores were determined for alveolitis, interstitial pneumonitis and perivasculitis in a blinded fashion. Average pathology scores were plotted. Panel B. FI-RSV induced alveolitis
in  lung tissue collected on day 54, 5 days post challenge. Panel C. RSV F vaccinated cotton rat lung section on day 54, 5 days post challenge.
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0.03, 0.3 or 3.0 g. or Panel D. Palivizumab monoclonal antibody at 0.625, 1.25, 2.5, or 5 mg/kg Animals in the placebo group received PBS. Error bar represent the 95% CI.
*p  < 0.01 compared to 5 mg/kg palivizumab group. +p < 0.05 compared to 5 mg/kg palivizumab group.
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Fig. 6. RSV-B 18537 virus Neutralizing antibodies, PCA and protection in passively
immunized  cotton rats. Cotton rats (n = 5) were passively immunized on day −1 with
5.6; 1.6; 0.6 mg/kg PCA antibodies, or 5; 1.25; 0.625 mg/kg palivizumab antibody.
Placebo  (Pl) rats received 0.15 ml  of pooled pre-immune serum (NCS). Sera from
24 hour post transfer day 0 samples were analyzed and the GMT  represented in
Panel A. Palivizumab competitive antibody PCA (Filled bars) and RSV-B 18537 virus
neutralizing antibody (Empty bars). *p < 0.01 compared with 5.0 mg/kg group and
+p < 0.01 compared to 1.3 mg/kg group by two-tailed student t-test. Panel B. The RSV-
B 18537 viral titers for each group represented as log10 pfu/g lung tissue. *p < 0.01
compared with placebo group by two-tailed Student t-test. NS: not signiﬁcant dif-
ference with negative control group. LOD is the lower limit of detection.ar and *p < 0.01 compared to 3 g RSV F group, p < 0.05 compared to 0.3 g RSV F
roup. LOD is the lower limit of detection. The limit of detection of this assay was
.0 log10.
omplete protection (Fig. 6B), reducing virus replication in the
ungs >100-fold relative to the placebo. Virus replication was  also
igniﬁcantly reduced in animals given 1.6 and 0.6 mg/kg anti-RSV
 immune sera compared to the group that received pre-immune
era (p < 0.01) (Fig. 6B). Palivizumab at 1.3 and 0.6 mg/kg induced a
light reduction in lung virus titers, but were not statistically signif-
cant when compared to the group that received pre-immune sera
Fig. 6B).
.6.  Competitive binding of vaccine-induced antibody to other
SV  F neutralizing epitopes
Beeler  et al. [35] have identiﬁed multiple neutralizing epitopes
n RSV F protein using competitive binding assays with a panel
f RSV F monoclonal antibodies and monoclonal antibody resis-
ant mutant (MARMs) and subsequently, antigenic sites I, II, IV,
 and IV were mapped on RSV F [36]. A competitive ELISA was
erformed using monoclonal antibodies 1107, 1112, 1153, 1243 to
dentify neutralizing antibodies induced by the RSV F vaccine. Anti-
odies 1107, 1153 and 1243 map  to antigenic sites II and I while
he 1112 is more broadly reactive to sites IV, V, and VI (Table 1).
olyclonal cotton rat sera raised against RSV F nanoparticle vac-
ine was competitive against these RSV F monoclonal antibodies
Table 1). Antibodies competitive for antigenic site II monoclonal
ntibodies 1107 and 1153 were induced by the vaccine without andPanel C. Anti-RSV F IgG log10 GMT  for each group are represented with the bar
graph  shown. *p < 0.01 compared to 1.3 and 0.6 mg/kg palivizumab groups; NS = not
signiﬁcant compared to palivizumab 5 mg/kg group.
with adjuvant, respectively while no or minimal site II competitive
antibodies were detected in sera from FI-RSV immunized and RSV
infected animals (Table 1). The RSV F vaccine also induced poly-
clonal responses competitive with neutralizing antibodies 1112
R. Raghunandan et al. / Vaccin
Table  1
Competitive binding ELISA titers of RSV neutralizing mAb’s binding to RSV F.
Vaccine groups 1107
(site II)
1112 (sites
IV,  V, VI)
1153
(site II)
1243
(site I)
FI-RSV <20a <20 60 <20
RSV-A long <20 30 64 29
RSV F <20 164 347 133
RSV F + AdjuPhos 292 442 3205 1220
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Ta <20 denotes lower limit of detection (LOD) of the competition ELISA. mAb  com-
eting antibody (MCA) is reported as the polyclonal anti RSV F antibody titers
equired for 50% inhibition of binding of mAb  to RSV F.
nd 1243 that recognize RSV F antigenic sites I, IV, V and VI
Table 1).
.  Discussion
RSV-related lower respiratory tract disease is the most common
ause of hospitalization in infants, a common basis for infant and
ediatric medical visits and a signiﬁcant pathogen in the elderly
nd high-risk adults. Severe RSV infections in young children are
learly associated with ongoing and repeat episodes of wheezing
24,37,38]. These populations described above may  beneﬁt from
accination with an RSV F-vaccine and, each population will require
 unique vaccination strategy and, clinical development program.
Passive  antibody prophylaxis has been shown to effectively
educe serious RSV disease in humans and induction of the immune
esponses to antigenic site II should be strongly considered in the
evelopment of an RSV vaccine. Here we show that the RSV F
anoparticle vaccine induces immune responses that both target
ite II on the F protein and are associated with functional and
rotective immunity in the cotton rat. The serially developed RSV
rophylactic products, Respigam, palivizumab and motavizumab
ere ﬁrst evaluated in cotton rats, a model that reliably predicted
he clinical outcomes [16,34,39]. Based on these preclinical data,
assive prophylaxis studies were advanced using palivizumab and
otavizumab and were shown to reduce RSV-related hospitaliza-
ion by 55–83% in preterm, high risk and term infants [14,16,40,41].
n recent clinical studies, we found that vaccine elicited antibodies
o the RSV F nanoparticle vaccine avidly bind to the site II epi-
ope. This is clearly an important observation as it can associate
he vaccine-induced immune responses of this novel vaccine with
ata showing prevention of RSV disease in ﬁve randomized clinical
rials [14,16,40,41].
In  the current study, using an array of antibody assays, we
haracterized and explored the implications of the production of
accine-induced PCA in the cotton rat model. The studies use
mportant controls: palivizumab, to assess relative potency of the
accine, both in active and passive assessments, and the recently
vailable Lot 100 formalin inactivated vaccine, historically associ-
ted with clinical disease enhancement. This allowed comparative
valuation of safety, ‘functional’ immunity as measured by PCA
nd neutralization assays, and protection in this clinically relevant
odel. The vaccine was shown to be safe, potent, to elicit high
evels of neutralizing, PCA, anti-F antibodies and to be protective
n both homologous and non-homologous strain viral challenge.
he protection seen with active immunization could be reproduced
sing passively injected immune sera and appeared to be dose for
ose, as potent as or more potent than palivizumab. Finally, the
SV F vaccine was also found to elicit antibodies that are known to
ind other non-palivizumab F protein binding sites associated with
eutralization without evidence of disease enhancement.The observation that neither adult humans, after decades of RSV
nfection, nor cotton rats after live virus challenge, elicit PCA in a
obust manner is of great interest and warrants further study [18].
he absence of PCA after infection is not absolute and the questione 32 (2014) 6485–6492 6491
of  whether the presence of “natural” antibodies confers protection
should be the focus of future studies. Fusion activity is critical to the
viral pathogenesis and antibody binding to site II disrupts fusion
activity [17], together suggesting that selection pressure favors an
immunologically cryptic site II. The ‘universal’ nature of the vac-
cine (protects against homologous and non-homologous virus), the
absence of robust natural immunity to an antigen critical for patho-
genesis such as site II on the F protein, the genetic stability of the
palivizumab binding site [42] as compared to other sites such as
antigenic site Ø [43], and the safety and the apparent potency of the
vaccine, reinforce the premise that efﬁcacy testing of the vaccine is
warranted.
The clinical development of an RSV vaccine may  be divided
amongst three populations: infants, infants/preschool children and
the elderly. Maternal immunization, the active immunization of
pregnant women to provide trans-placental transferred antibody
for passive protection of the infant, is a priority strategy for pro-
tection of young infants against RSV and has been successfully
employed for tetanus, pertussis and inﬂuenza vaccines [44]. Older
infants and toddlers may  also beneﬁt from active immunization
and many strategies including live viral vaccines and puriﬁed sub-
unit vaccines have been employed in early clinical testing [45].
An RSV puriﬁed F protein showed clinical promise in children
and CF patients, but proved difﬁcult to manufacture and stabilize
[22,46]. The clinical evaluation of a novel vaccine must also take
into account the history of the formalin inactivated RSV vaccine
(Pﬁzer Lot 100 vaccine) that unexpectedly caused severe exacerba-
tion of pulmonary disease in children who subsequently acquired
RSV infections [33,47]. Although the precise mechanisms under-
lying these ﬁndings remain open to debate [48], the phenomenon
of vaccine-enhanced RSV disease was  limited to RSV-naïve infants
immunized with FI-RSV and has not been observed either with
passive antibody prophylaxis (monoclonal or polyclonal) in clin-
ical trials using puriﬁed F protein vaccines in adults or older
RSV-seropositive children [22,46,49]. Thus, the path forward for
development of a vaccine in older infants and children will need
to be carefully considered. However, a vaccine that induces high
afﬁnity antibodies that exhibit neutralization or fusion inhibition
in vitro, largely absent in FI-RSV vaccinated infants [50], and is
associated with protection without disease exacerbation in vivo
in relevant animal models and ﬁnally shows efﬁcacy in another
setting such as maternal immunization may be considered in the
absence of a licensed vaccine for this population. Finally, the RSV
disease burden in elderly and high risk adults and the data indicat-
ing an F subunit vaccine is safe along with the absence of historical
safety concerns due to enhanced disease in this population suggests
further testing of the safety and efﬁcacy as a seasonal respiratory
vaccine is warranted. The induction of PCA by the RSV F nanopar-
ticle vaccine provides an important rationale for further clinical
evaluation in the relevant susceptible populations.
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